Zydus Cadila gets USFDA’s approval for Nystatin and Triamcinolone Acetonide Ointment

12 Nov 2018 Evaluate

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Nystatin and Triamcinolone Acetonide Ointment USP, (US RLD -Mycolog-II Ointment), 100,000 units/gram and 1 mg/gram. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

It is used to treat fungal skin infections. This product contains nystatin, an anti-fungal drug that works by stopping the growth of fungus. It also contains triamcinolone, an anti-inflammatory corticosteroid that works by reducing swelling, itching, and redness.

The group now has 226 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

890.50 -2.95 (-0.33%)
28-Jan-2026 09:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1632.35
Dr. Reddys Lab 1233.60
Cipla 1314.10
Zydus Lifesciences 890.50
Lupin 2142.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×